Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (241-250 of 333) with videos related to

Pageof 34
Sort By:
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Viruses|April 27, 2017
Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma CellsRobert A Kozak, Larissa Hattin, Mia J Biondi, et al.
The Journal of Clinical Investigation|January 3, 2023
Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cellsShirin Nkongolo, Deeqa Mahamed, Adrian Kuipery, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2009
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppressionTara N Palmore, Neeral L Shah, Rohit Loomba, et al.
Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Hepatic abnormalities in patients with chronic granulomatous diseaseNadeem Hussain, Jordan J Feld, David E Kleiner, et al.
Journal of Hepatology|May 1, 2014
Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Adriaan J van der Meer, Bettina E Hansen, et al.
Journal of Viral Hepatitis|August 29, 2022
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohortsJordan J Feld, Xavier Forns, Douglas E Dylla, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Pageof 34

Showing results (241-250 of 333) with videos related to

Sort By:
Pageof 34
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Viruses|April 27, 2017
Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma CellsRobert A Kozak, Larissa Hattin, Mia J Biondi, et al.
The Journal of Clinical Investigation|January 3, 2023
Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cellsShirin Nkongolo, Deeqa Mahamed, Adrian Kuipery, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2009
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppressionTara N Palmore, Neeral L Shah, Rohit Loomba, et al.
Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Hepatic abnormalities in patients with chronic granulomatous diseaseNadeem Hussain, Jordan J Feld, David E Kleiner, et al.
Journal of Hepatology|May 1, 2014
Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosisRaoel Maan, Adriaan J van der Meer, Bettina E Hansen, et al.
Journal of Viral Hepatitis|August 29, 2022
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohortsJordan J Feld, Xavier Forns, Douglas E Dylla, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Pageof 34